Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients.

e21196Background: Non-small cells lung cancer (NSCLC) patients treated with Tyrosine Kinase Inhibitors (TKI) at first-line ultimately develop disease progression after 10 to 14 months. Mechanisms u...